Developing a bidirectional nanoparticle-basedBCI with NO surgical procedure in collaboration with leading global academic institutions
Subsense, Inc., a neurotechnology company developing the first non-surgical, nanoparticle-based Brain-Computer Interface (BCI), emerged from stealth today to formally reveal its efforts in the emerging field of non-invasive brain connectivity. Co-founded by neurotech entrepreneur Tetiana Aleksandrova and serial entrepreneur Artem Sokolov, Subsense has raised $17M in seed funding led by Sokolov's Golden Falcon Capital to accelerate the development of bidirectional nanoparticle-based technologies that connect the human brain with external sources. Subsense is working with a consortium of leading international neurological research institutions which include UC Santa Cruz and ETH Zurich, Switzerland's Federal Institute of Technology.
"Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches," said Tetiana Aleksandrova, Subsense's Chief Executive Officer. "By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach."
Through targeted neural stimulation and precise monitoring via nanoparticles, Subsense is developing therapeutics for patients with neurological conditions such as Parkinson's, Alzheimer's, epilepsy, depression, strokes, chronic pain and more.
"The integration of nanoparticles into brain-computer interfaces marks a significant advancement in neuroscience. The system-on-a-nanoparticle approach could greatly enhance the precision of neural communication, offering new possibilities for treating neurodegenerative diseases and expanding human cognitive capabilities," said Prof. Ali A. Yanik, Department of Electrical and Computer Engineering, UC Santa Cruz, a Subsense research partner.
The company is also targeting more expansive applications for later stages such as:
- Sensorimotor recovery of vision, hearing and movement;
- Inner speech decoding and thought translation;
- Integration with AI by merging brain and artificial neural networks;
- External memory as an instant backup and extended capacity;
- Mental health regulation happiness monitoring and control;
- Appetite control identification and managing of regulatory mechanisms.
"Subsense is adopting a very different approach to unlock a key area of medical potential, the ability to interact with the brain. By offering an alternative to complicated and acute neurosurgical implantations, Subsense holds promise for tens of millions of neuro-compromised patients," said Artem Sokolov, General Partner, Golden Falcon Capital and Subsense co-founder. Sokolov has been an investor in companies that include: SpaceX, Asana, SoFi, Coursera, Lemonade, Digital Ocean among many others.
To learn more about Subsense's novel non-surgical approach to Brain-Computer Interfaces visit www.subsense-bci.com
ABOUT SUBSENSE
Subsense, Inc. is a neurotechnology company developing the first non-surgical, nanoparticle-based bidirectional brain-computer interface. Subsense is partnered with leading global neurological research institutions.
The company is venture-backed with its global headquarters in Palo Alto, California. It is co-founded by neurotech entrepreneur Tetiana Aleksandrova and serial entrepreneur Artem Sokolov, who has been an early investor in companies that include: Asana, SoFi, Coursera, Lemonade, Digital Ocean among many others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218878648/en/
Contacts:
Media Contact
subsense@consortpartners.com
